The rapid viral decline with the HCV NS5A inhibitor daclatasvir reveals a dual mode of action and leads to a new HCV half-life estimate

Documenti analoghi

• Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
  di: Guedj, Jeremie, et al.
  Pubblicazione: (2013)
• Silibinin mode of action(s) against HCV: A controversy yet to be resolved
  di: Dahari, Harel, et al.
  Pubblicazione: (2011)
• Understanding silibinin’s modes of action against HCV using viral kinetic modeling
  di: Guedj, Jeremie, et al.
  Pubblicazione: (2012)
• Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy
  di: Guedj, Jeremie, et al.
  Pubblicazione: (2011)
• Treatment of hepatitis C with an interferon-based lead-in phase: A perspective from mathematical modeling
  di: Rong, Libin, et al.
  Pubblicazione: (2014)